Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

A. Du Bois, Jalid Sehouli, B. Lund, E. Joly, J. Huober, TS Jensen, E. Levy, V. Heilmann, Kurt Boman, AC Hardy-Bessard, A. Burges, Johanna Maenpaa, Eric Pujade-Lauraine, Jacobus Pfisterer, M Gropp, A. Staehle, P. Wimberger, C. Jackisch, B. Schmalfeldt, A. BelauS. Loibl, K. Wollschlaeger, U. Canzler, J. Rochon, GCIG Intergrp AGO-OVAR NSGO GINE

Research output: Contribution to journalJournal articleResearchpeer-review

5 Citations (Scopus)
Original languageUndefined/Unknown
JournalInternational Journal of Gynecological Cancer
Issue numberSuppl. 3
Pages (from-to)224-225
Number of pages2
Publication statusPublished - 1 Nov 2005
Externally publishedYes

Bibliographical note

PT: J; NR: 0; TC: 3; J9: INT J GYNECOL CANCER; SU: 3; PG: 2; GA: 991HQ; UT: WOS:000233803600007

Cite this